GENERIC DRUG SUBSTITUTION REVISITED

被引：51

作者：

STROM, BL ^{[1
]}

机构：

[1] UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104

来源：

关键词：

D O I：

10.1056/NEJM198706043162306

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1456 / 1462

页数：7

共 50 条

[1] CRITICAL-EVALUATION OF THIORIDAZINE BIOEQUIVALENCE
BARONE, JA
COLAIZZI, JL
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (11): : 847 - 858
[2] BLANCHARD J, 1979, PRINCIPLES PERSPECTI, P1
[3] COST AND PRICE OF COMPARABLE BRANDED AND GENERIC PHARMACEUTICALS
BLOOM, BS
WIERZ, DJ
PAULY, MV
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (18): : 2523 - 2530
[4] Cabana B E, 1983, Health Aff (Millwood), V2, P33, DOI 10.1377/hlthaff.2.3.33
[5] ASSESSMENT OF 75/75 RULE - FDA VIEWPOINT
CABANA, BE
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (01) : 98 - 99
[6] CHIEN CP, 1985, INTEGRATIVE PSYCHIAT, V3, pS58
[7] A TIME TO SPEAK OUT ON BIOEQUIVALENCE AND THERAPEUTIC EQUIVALENCE
DETTELBACH, HR
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (05) : 307 - 308
[8] DEVEAUGHGEISS J, 1985, CLIN THER, V7, P544
[9] EDWARDS CC, 1970, FED REG 0424, V35, P6574
[10] FREESTON.DS, 1969, LANCET, V2, P98